A handheld cold plasma device in which the device includes power source, control electronic circuit boards connected to high-frequency high-voltage transformers, user control panels, insulating case covering control electronic circuits, high-frequency high-voltage transformer and user control panel to form a monoblock, the plasma generating unit contains the active electrode and the passive electrode outside the housing to allow the user to be connected to the neutral wires of the device. The device according to the present disclosure uses the principle of direct discharge (or dielectric barrier discharge with floating electrodes) with small size, inexpensive and does not use consumable materials.

An electrotechnical core for generating a cold atmospheric pressure or low-pressure plasma for the treatment of human, animal, or technical surfaces. The core has a side facing the surface and a side facing away from the surface and comprises the following layers, starting from the side facing the surface: a first insulation layer, a first electrode structure with a first contact between the first electrode structure and a power supply unit, a second insulation layer to galvanically isolate the first electrode structure and a second electrode structure from one another, wherein the second electrode structure is driven during operation by a voltage signal sufficient to ignite a plasma, a third insulation layer to galvanically isolate the second electrode structure from a third electrode structure, wherein the third electrode structure grounds the third electrode structure during operation.

A cold atmospheric plasma (CAP)-mediated ICB therapy/delivery device are disclosed herein that employs a patch having microneedles that are used to deliver the CAP transdermally along with an immune checkpoint inhibitor for enhancing transdermal treatment efficacy. The hollow-structured microneedle patch can facilitate the transportation of CAP through the skin, causing tumor cell death. The release of cancer antigens then promotes the maturation of dendritic cells in the tumor-draining lymph nodes, subsequently initiating the T cell-mediated immune response. Anti-PDL1 antibody (aPDL1), an immune checkpoint inhibitor (or other immune checkpoint inhibitors), released from the microneedle patch (in some embodiments) further augments the anti-tumor immunity. The transdermal combinational CAP and ICB therapy inhibits tumor growth for both primary tumors as well as distant tumors, with prolonged survival in the tumor-bearing mice. Such results should translate to other species.

A cold atmospheric plasma (CAP)-mediated ICB therapy/delivery device are disclosed herein that employs a patch having microneedles that are used to deliver the CAP transdermally along with an immune checkpoint inhibitor for enhancing transdermal treatment efficacy. The hollow-structured microneedle patch can facilitate the transportation of CAP through the skin, causing tumor cell death. The release of cancer antigens then promotes the maturation of dendritic cells in the tumor-draining lymph nodes, subsequently initiating the T cell-mediated immune response. Anti-PDL1 antibody (aPDL1), an immune checkpoint inhibitor (or other immune checkpoint inhibitors), released from the microneedle patch (in some embodiments) further augments the anti-tumor immunity. The transdermal combinational CAP and ICB therapy inhibits tumor growth for both primary tumors as well as distant tumors, with prolonged survival in the tumor-bearing mice. Such results should translate to other species.

Disclosed is a method for treating actinic keratosis of tissue of a patient, the method including contacting non-thermal, atmospheric pressure plasma over areas of the tissue having actinic keratosis for a time and at treatment conditions effective to give rise to an at least partial amelioration of the keratosis.

Disclosed is a method for treating actinic keratosis of tissue of a patient, the method including contacting non-thermal, atmospheric pressure plasma over areas of the tissue having actinic keratosis for a time and at treatment conditions effective to give rise to an at least partial amelioration of the keratosis.

An exemplary embodiments of the present disclosure are directed to providing a skin care apparatus using plasma and near-infrared ray designed to provide effects of improving skin and lifting by irradiating plasma and near-infrared ray generated through dual electric generation on skin contacted by a spherical form. Further, the exemplary embodiments of the present disclosures are directed to providing a skin care apparatus using plasma and near-infrared ray that prevents skin contact or dual irradiation, which were used to happen in the conventional side contact structure, with the method of irradiating plasma and near-infrared ray by using dielectric barrier discharge for each of the plasma discharge groove and near-infrared irradiation groove that are different from the conventional contact structure, through a spot contact spherical body structure.

An exemplary embodiments of the present disclosure are directed to providing a skin care apparatus using plasma and near-infrared ray designed to provide effects of improving skin and lifting by irradiating plasma and near-infrared ray generated through dual electric generation on skin contacted by a spherical form. Further, the exemplary embodiments of the present disclosures are directed to providing a skin care apparatus using plasma and near-infrared ray that prevents skin contact or dual irradiation, which were used to happen in the conventional side contact structure, with the method of irradiating plasma and near-infrared ray by using dielectric barrier discharge for each of the plasma discharge groove and near-infrared irradiation groove that are different from the conventional contact structure, through a spot contact spherical body structure.

A system and method includes a nonthermal plasma sub-system with a permeable UV filter for production and delivery of a redox gas solution to treat onychomycosis, wherein the redox gas solution comprises a reactive species dissolved in a perfluorocarbon liquid, and wherein the perfluorocarbon liquid is dispensed onto a gas-permeable membrane and wherein the reactive species may include, alone, or in combination, one or more of reactive oxygen, reactive nitrogen, reactive chlorine, or reactive bromine species, and the perfluorocarbon liquid may include perfluorodecalin.

A method and system for tattoo removal from a subject by exposing tattoo ink particles trapped within the dermis to a cold plasma is described herein. The tattoo removal method and system can be used to remove the tattoo from the skin of the subject being treated. In addition, the method and system described allows for the extraction of the tattoo ink particles, which may have toxic properties, from the subject's body.